Methotrexat Accord

Methotrexate, the active ingredient in Methotrexat Accord, is an antimetabolite presented as a sterile solution for intraarterial, intramuscular, and intrathecal use. It is indicated for adult patients with rheumatoid arthritis, psoriasis, acute lymphoblastic leukemia, osteosarcoma, and other malignancies.

GNH USA supplies Methotrexat Accord as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, oncology centres, and pharmacies worldwide. The company adheres to stringent quality standards, offers comprehensive regulatory support, and provides reliable logistics for global distribution.

Methotrexate is used in several disease categories where it modulates cell proliferation and immune activity.

Rheumatoid arthritis: reduces joint inflammation and slows disease progression. Psoriasis: improves skin lesions and decreases plaque formation. Acute lymphoblastic leukemia: contributes to remission by inhibiting malignant lymphoblast proliferation. Osteosarcoma: used as part of combination chemotherapy to limit tumor growth. Other malignancies: employed in various solid tumor regimens to enhance cytotoxic efficacy.

Methotrexate may cause a range of adverse reactions, varying from mild to severe.

Common Side Effects: - Nausea or vomiting - Fatigue or weakness - Mouth sores (stomatitis) - Elevated liver enzymes - Low blood cell counts (e.g., neutropenia, anemia)

Serious or Rare Side Effects: - Severe liver toxicity or fibrosis - Pulmonary fibrosis or interstitial pneumonitis - Life‑threatening infections due to immunosuppression

When prescribing methotrexate, clinicians should observe several precautionary measures to minimize risk. - Renal function: assess baseline creatinine and monitor regularly. - Hepatic health: perform liver function tests before initiation and periodically. - Hematologic status: obtain complete blood count prior to therapy and during treatment. - Concomitant drugs: avoid use with other hepatotoxic or myelosuppressive agents when possible. - Pregnancy and lactation: contraindicated in pregnancy; advise effective contraception and discuss risks if breastfeeding. - Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Methotrexate has notable drug interactions that may require dose adjustment or avoidance.

Major Interactions (Avoid): - Non‑steroidal anti‑inflammatory drugs (NSAIDs): increase methotrexate toxicity by reducing renal clearance. - Proton pump inhibitors (e.g., omeprazole): may elevate methotrexate plasma levels. - Trimethoprim‑sulfamethoxazole: synergistic myelosuppression risk.

Moderate Interactions (Monitor Closely): - Penicillins (high‑dose): can reduce methotrexate elimination. - Azathioprine or mycophenolate: additive immunosuppression. - Live vaccines: increased infection risk; avoid during therapy.